Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
19 nov. 2024 07h17 HE
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions ...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
14 nov. 2024 07h15 HE
|
Appili Therapeutics Inc.
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
06 nov. 2024 17h55 HE
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
31 oct. 2024 07h15 HE
|
Appili Therapeutics Inc.
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
17 oct. 2024 07h15 HE
|
Appili Therapeutics Inc.
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy ...
Appili Therapeutics – Press Release Correction
10 oct. 2024 15h40 HE
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili...
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
10 oct. 2024 07h13 HE
|
Appili Therapeutics Inc.
Your vote is important no matter how many votes you hold.Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova Scotia,...
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
17 sept. 2024 17h11 HE
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
21 août 2024 07h15 HE
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
13 août 2024 17h19 HE
|
Appili Therapeutics Inc.
Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ATI-1701 funding commitments from U.S. Air...